Trion Research GmbH

Originally founded in 1998 as an independent entity by Horst Lindhofer, we have assisted in the preclinical and clinical development of all Triomab® antibodies that are under development or received market approval, including that of Removab®, the first bispecific, trifunctional antibody on the market worldwide. We have also generated further candidates of the Triomab® family.